[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604521":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":23,"locations":28,"responsibleParty":58,"collaborators":61,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":10,"enrollmentInfo":75,"targetDuration":10,"studyType":78,"phases":10,"briefSummary":79,"conditions":80,"keywords":84,"overallStatus":94,"whyStopped":10,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Technische Universität Dresden","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Kohort A",null,"Patients with advanced non-small cell lung cancer (NSCLC) who undergo tumor biopsy at initial diagnosis and a second biopsy approximately 6 weeks after starting standard-of-care immunochemotherapy. Biospecimens will be analyzed using multiplex immunofluorescence and 3'-RNA sequencing to study immune and tumor-associated biomarkers.",{"label":13,"type":10,"description":14,"interventionNames":10},"Kohort B","Patients with advanced NSCLC who undergo tumor biopsy at the time of disease progression or therapy line change while receiving standard-of-care immunochemotherapy. Biospecimens will be analyzed using multiplex immunofluorescence and 3'-RNA sequencing to study immune and tumor-associated biomarkers.",[16,20],{"name":17,"affiliation":18,"role":19},"Martin Wermke, Prof. Dr.","Medizinische Klinik I, Universitätsklinikum Carl Gustav Carus, Dresden","PRINCIPAL_INVESTIGATOR",{"name":21,"affiliation":22,"role":19},"Jürgen Wolf, Prof. Dr.","Klinik I für Innere Medizin, CIO, Universitätsklinikum Köln",[24],{"name":17,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","+49 351 458 16226","impalux-studie@ukdd.de",[29,46],{"facility":30,"status":10,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Universitätsklinikum Köln, Centrum für Integrierte Onkologie (CIO) Köln","Cologne","North Rhine-Westphalia","50937","Germany","DE",{"type":37,"coordinates":38},"Point",[39,40],6.95,50.93333,{"lat":40,"lon":39},[43],{"name":21,"role":25,"phone":44,"phoneExt":10,"email":45},"+49221 478 89050","lungenkrebs@uk-koeln.de",{"facility":47,"status":10,"city":48,"state":49,"zip":50,"country":34,"countryCode":35,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"Universitätsklinikum Carl Gustav Carus","Dresden","Saxony","01307",{"type":37,"coordinates":52},[53,54],13.73832,51.05089,{"lat":54,"lon":53},[57],{"name":17,"role":25,"phone":26,"phoneExt":10,"email":27},{"type":19,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Dr. med. Martin Wermke","Prof. Dr. med.",[62,64],{"name":63,"class":6},"Deutsche Krebshilfe e.V., Bonn (Germany)",{"name":65,"class":6},"Universitätsklinikum Köln","100604521","immune-marker-platform-for-patients-with-advanced-lung-cancer-100604521",false,"NCT07150598","Immune-Marker Platform for Patients With Advanced Lung Cancer","IMPALUX","Inclusion Criteria:\n\nFor all:\n\n* Written informed consent of the patient\n* Consent of participation in the national Network for Genomic Medicine in Lung Cancer (nNGM)\n* Advanced lung cancer with non-curative treatment option (NSCLC)\n* No targetable driver mutation detected, defined as no targetable drive mutation in ALK, EGFR, BRAF, HER2, MET, NTRK, RET, ROS1\n* PD-L1 expression on tumor cells (TPS \\\u003C 50%)\n\nCohort A:\n\n* Previously untreated NSCLC without curative treatment options\n* Sufficient pre-treatment tumor material available for the planned analyses or consenting and able to undergo additional pretreatment biopsy\n* Scheduled to undergo immune(chemo)therapy\n* Willing and able to undergo re-biopsy 6 weeks after start of immune(chemo)therapy\n\nCohort B:\n\n* Any line of progression after firstline immune(chemo)therapy\n* Sufficient tumor material obtained after progression on most recent line of treatment available or willing and able to undergo re-biopsy prior to next line treatment\n\nExclusion Criteria:\n\n* Any condition representing an unjustified risk for obtaining an additional biopsy sample (if needed) in the view of the investigator\n* Incapability of understanding the purpose and possible consequences of the trial\n* Substance abuse, medical, psychological or social conditions that may interfere with the subject's cooperation with the requirements of the trial or evaluation of the study results","ALL","18 Years",{"count":76,"type":77},500,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to better understand how the immune system and certain tumor markers are linked to treatment response in patients with advanced non-small cell lung cancer (NSCLC) who receive immunochemotherapy.\n\nThe investigators aim to answer the following questions:\n\n* Can the investigators successfully analyze immune markers and gene activity from small tumor samples (biopsies)?\n* Are these markers connected to how well patients respond to immunochemotherapy and how their disease progresses?\n\nWhat will participants do?\n\n* Provide tumor tissue samples (biopsies) at key points: before treatment, about 6 weeks after starting immunochemotherapy, and if the cancer grows or treatment changes.\n* Allow their tumor samples to be analyzed in the lab using advanced techniques to measure immune and genetic markers.\n* Share clinical information (such as treatment response and disease progression) so investigators can study how it relates to these markers.\n\nThis study does not test a new drug or treatment.",[81,82,83],"NSCLC (Advanced Non-small Cell Lung Cancer)","NSCLC Stage IIIB~IV","NSCLC Non-small Cell Lung Cancer",[85,86,87,88,89,90,91,92,93],"Non-Small Cell Lung Cancer","NSCLC","Immunochemotherapy","Multiplex Immunofluorescence","3'-RNA Sequencing","Prospective Observational Study","Tumor Microenvironment","Therapy Response","Precision Oncology","NOT_YET_RECRUITING","2025-09-01",{"date":97,"type":98},"2025-09-08","ACTUAL",{"date":95,"type":77},{"date":101,"type":77},"2027-06-01",{"name":5,"class":6},2]